B. Riley Estimates LifeMD’s Q1 Earnings (NASDAQ:LFMD)

LifeMD, Inc. (NASDAQ:LFMD) – Equities researchers at B. Riley issued their Q1 2025 earnings per share estimates for shares of LifeMD in a research note issued to investors on Tuesday, March 11th. B. Riley analyst A. Schock anticipates that the company will post earnings per share of ($0.07) for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.56) per share. B. Riley also issued estimates for LifeMD’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at $0.00 EPS, Q4 2025 earnings at $0.03 EPS and FY2025 earnings at ($0.10) EPS.

LifeMD (NASDAQ:LFMD) last issued its earnings results on Monday, March 10th. The company reported ($0.02) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.02. The firm had revenue of $64.26 million during the quarter, compared to analysts’ expectations of $57.43 million.

Other analysts also recently issued reports about the company. HC Wainwright raised their target price on LifeMD from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday. Mizuho assumed coverage on LifeMD in a research note on Wednesday, December 4th. They set a “neutral” rating and a $7.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 target price on shares of LifeMD in a research note on Tuesday, March 11th. Lake Street Capital started coverage on LifeMD in a research note on Tuesday, December 10th. They issued a “buy” rating and a $12.00 price target for the company. Finally, KeyCorp decreased their price target on LifeMD from $10.00 to $7.00 and set an “overweight” rating for the company in a research note on Wednesday, January 8th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $11.43.

LifeMD Price Performance

Shares of LifeMD stock opened at $5.94 on Friday. The business has a 50-day moving average of $5.68 and a 200-day moving average of $5.39. The company has a market capitalization of $264.83 million, a PE ratio of -9.28 and a beta of 1.50. LifeMD has a 1-year low of $3.99 and a 1-year high of $12.88.

Insider Buying and Selling at LifeMD

In other LifeMD news, CEO Justin Schreiber sold 25,000 shares of LifeMD stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $5.19, for a total value of $129,750.00. Following the completion of the transaction, the chief executive officer now directly owns 2,703,715 shares in the company, valued at $14,032,280.85. The trade was a 0.92 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 15.97% of the stock is currently owned by insiders.

Hedge Funds Weigh In On LifeMD

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Prudential Financial Inc. raised its holdings in shares of LifeMD by 19.3% during the fourth quarter. Prudential Financial Inc. now owns 13,605 shares of the company’s stock valued at $67,000 after buying an additional 2,200 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of LifeMD by 6.1% during the fourth quarter. Rhumbline Advisers now owns 48,689 shares of the company’s stock valued at $241,000 after buying an additional 2,814 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in LifeMD by 26.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,012 shares of the company’s stock worth $70,000 after purchasing an additional 2,895 shares in the last quarter. Geode Capital Management LLC raised its holdings in LifeMD by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 822,217 shares of the company’s stock worth $4,071,000 after purchasing an additional 2,984 shares in the last quarter. Finally, Magnus Financial Group LLC raised its holdings in LifeMD by 31.1% during the fourth quarter. Magnus Financial Group LLC now owns 16,000 shares of the company’s stock worth $79,000 after purchasing an additional 3,792 shares in the last quarter. 35.52% of the stock is currently owned by institutional investors and hedge funds.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.